Avacta Group Share News (AVCT)

Avacta Group Information

Buy AVCT Shares
Add AVCT to Watchlist
Add AVCT to Alert

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 42.50

Bid: 42.00

Ask: 43.00

Change: 0.50 (1.19%)

Spread: 1.00 (2.381%)

Open: 41.75

High: 42.50

Low: 41.25

Prev. Close: 42.00

Last checked at -

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

Thu, 02nd Sep 2021 11:50

Avacta Group PLC - Wetherby, England-based cancer immunotherapies developer - Hires Fiona McLaughlin as Chief Scientific Officer of its therapeutics division, effective immediately. McLaughlin is a medical oncology drug developer and most recently vice president of New Opportunities at Algeta ASA, a biotech firm which worked on castration resistant prostate cancer treatment.

"Fiona is a seasoned drug developer with an outstanding track record in developing oncology drug candidates and taking them into clinical development," says Chief Executive Alastair Smith.

Current stock price: 135.74 pence

Year-to-date change: up 19%

By Josie O'Brien; josieobrien@alliancenews.com

More News

11 Aug 2021 11:29

Avacta doses first patient in chemotherapy medication trial

11 Aug 2021 10:00

First patient dosed in Avacta's 'AVA6000' trial

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that the first patient has been dosed in its phase 1 multicentre trial evaluating 'AVA6000', which it described as a "novel pro-drug" of 'doxorubicin', and its first therapeutic product based on the proprietary 'preCISION' technology.

4 Aug 2021 17:53

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

14 Jul 2021 11:30

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

14 Jul 2021 11:10

IN BRIEF: Avacta wins manufacturer certification for lateral flow test

14 Jul 2021 09:02

Avacta gets ISO certification for Affirmer manufacture and distribution

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced on Wednesday that its life sciences diagnostics division has achieved ISO 13485 certification on the quality management system for the manufacture and distribution of 'Affimer' reagents, for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.

29 Jun 2021 12:12

IN BRIEF: Avacta's lateral flow test detects Covid Delta variant

29 Jun 2021 11:37

AIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbs

29 Jun 2021 08:36

Avacta rapid Covid-19 test detects Delta variant in study

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group announced on Tuesday that a study has shown that its 'AffiDX' antigen lateral flow test detects the 'Delta' variant of the SARS-CoV-2 virus in clinical samples.

23 Jun 2021 10:28

AIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers

21 Jun 2021 19:24

IN BRIEF: Avacta signs distribution deal for its Covid test

21 Jun 2021 16:11

UK shareholder meetings calendar - next 7 days

21 Jun 2021 08:37

Avacta enters non-exclusive distribution deal for Covid-19 test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has entered into a non-exclusive distribution agreement with life science products company Calibre Scientific, it announced on Monday, for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use in the UK and the European Economic Area (EEA).

11 Jun 2021 12:27

Avacta to sell rapid Covid-19 test in EU following registration

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has received notice of registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test in the European Union, allowing it to place the product on the market for professional use in all 27 countries of the EU.

11 Jun 2021 11:40

Latest Share Chat

Avacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

Avacta doses first patient in chemotherapy medication trial

First patient dosed in Avacta's 'AVA6000' trial

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

IN BRIEF: Avacta wins manufacturer certification for lateral flow test

Avacta gets ISO certification for Affirmer manufacture and distribution

IN BRIEF: Avacta's lateral flow test detects Covid Delta variant

AIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbs

Avacta rapid Covid-19 test detects Delta variant in study

AIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers

IN BRIEF: Avacta signs distribution deal for its Covid test

UK shareholder meetings calendar - next 7 days

Avacta enters non-exclusive distribution deal for Covid-19 test

Avacta to sell rapid Covid-19 test in EU following registration

Avacta Covid lateral flow test gets regulatory green light in EU

Latest Share Chat

Avacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

Login to your account

Quickpicks are a member only feature

Login to your account